Now showing items 1-3 of 3

  • Valproate MHRA Guidance: Limitations and Opportunities. 

    Watkins, L; Cock, H; Angus-Leppan, H; Morley, K; Wilcock, M; Shankar, R (Switzerland, 2019)
    Recent publication of the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has strengthened the regulatory measures for valproate medicines. It highlights the importance of making women of ...
  • Valproate prescribing practices for women with intellectual disability across Europe. 

    Watkins, L; Reuber, M; Perera, B; Courtenay, K; Banks, R; Murphy, E; Angus-Leppan, H; Shankar, R (Denmark, 2021-01)
    BACKGROUND: Valproate (VPA) is a known teratogen associated with greater risk of major congenital malformations and other neurodevelopmental sequelae than all other licensed antiepileptic medicines. To reduce the potential ...
  • Valproate risk form-Surveying 215 clinicians involving 4775 encounters. 

    Angus-Leppan, H; Moghim, MM; Cock, H; Kinton, L; Synnott Wells, M; Shankar, R (Denmark, 2020-06)
    OBJECTIVES: Annual completion of a Valproate Risk Acknowledgement Form (RAF) is mandated in the United Kingdom due to neurodevelopmental risks of in utero valproate exposure. The number of women of childbearing potential ...

All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
@mire NV